CA Patent

CA2703313C — Oral dosage forms comprising licarbazepine acetate

Assigned to Bial Portela and Cia SA · Expires 2017-03-07 · 9y expired

What this patent protects

A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the ph…

USPTO Abstract

A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition

Drugs covered by this patent

Patent Metadata

Patent number
CA2703313C
Jurisdiction
CA
Classification
—
Expires
2017-03-07
Drug substance claim
No
Drug product claim
No
Assignee
Bial Portela and Cia SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.